Impact of Tozinameran mRNA Design on Antigenicity

How does Tozinameran's mRNA design (e.g., prefusion-stabilized spike) affect antigenicity?

Tozinameran's prefusion-stabilized spike design (K986P/V987P mutations) and N1-methylpseudouridine modifications enhance antigenicity by concentrating immune responses on neutralizing epitopes and prolonging antigen expression, producing neutralizing antibody titers 10-18 times higher than natural infection despite recognizing fewer total epitopes.

Abstract

Tozinameran’s mRNA design achieves high antigenicity through multiple synergistic elements centered on prefusion-stabilized spike protein presentation. The K986P and V987P mutations lock the spike in a conformation where approximately 20% of trimers adopt the one-RBD ‘up’ state, authentically presenting the ACE2 binding site and neutralizing epitopes. This design elicits neutralizing antibody titers 10-18 times higher than convalescent sera in non-human primates and preserves neutralization against some variants, supported by clinical efficacy exceeding 95%. N1-methylpseudouridine modification enhances mRNA stability and translation while reducing innate immune sensing, contributing to the superiority of nucleoside-modified vaccines (>94% efficacy) over unmodified designs (48% efficacy). Additional elements including optimized UTRs and TENT5A-mediated poly(A) tail extension prolong antigen production and enhance immunogenicity.

Critically, the prefusion-stabilized design produces a distinct immune profile compared to natural infection: vaccine-elicited sera recognize fewer total linear epitopes (11 vs 37) but achieve higher neutralizing potency by focusing responses on functionally critical determinants like K417, E484, and N501 residues. The 26 epitopes recognized exclusively by convalescent sera map predominantly to post-fusion conformational states masked by prefusion stabilization, representing non-neutralizing targets. This epitope focusing represents an intentional design feature prioritizing neutralizing antibody quality over total antibody diversity. The design also generates strong TH1-type CD4+ and IFNγ+ CD8+ T-cell responses with broader epitope coverage from the full-length spike compared to RBD-only constructs. Advanced stabilization approaches like the S6P mutation further enhance durability and cross-variant neutralization, while self-amplifying platforms demonstrate sustained immune activation through prolonged antigen expression.

Methods

We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200 Papers screened using: Tozinameran Focus, mRNA Design Features, Antigenicity Outcomes, Study Design, Research Context, Comparative Analysis, Beyond Efficacy/Safety Only, mRNA Vaccine Relevance, Adequate Study Type
• n = 200 Papers screened out
• n = 190 Papers included for extraction

Results

Characteristics of Included Studies

The included studies spanned preclinical models (mice and non-human primates), human observational studies, clinical trials, and systematic reviews. Six studies used full text, while one was available as abstract only. Studies employed diverse vaccination schedules, with preclinical studies typically using prime-boost regimens at days 0 and 21, while human studies examined booster responses in previously vaccinated individuals.

mRNA Design Features of Tozinameran

Tozinameran (BNT162b2) incorporates several molecular design elements intended to enhance antigenicity. The vaccine encodes a full-length spike protein stabilized in its prefusion conformation through K986P and V987P substitutions, also referred to as P2 mutations. Structural analysis revealed that approximately 20% of expressed spike trimers adopt the one-RBD ‘up’, two-RBD ‘down’ conformation, which authentically presents the ACE2 binding site and other neutralizing epitopes.

The mRNA contains nucleoside modifications, specifically N1-methylpseudouridine (m1Ψ), which reduces innate immune sensing and enhances RNA translation. The construct includes a 100-nucleotide poly(A) tail, though one study noted BNT162b2 has a composite poly(A) tail structure. The 5’ untranslated region (UTR) derives from human hemoglobin α-globin (HBA1), while the 3’ UTR originates from AES-mtRNR1. Additional optimization includes non-coding sequence elements and a linker (A30LA70) to improve RNA stability and translational efficiency.

Comparative design studies revealed differences between Tozinameran and other mRNA vaccines. BNT162b2 employs the ionizable lipid ALC-0315, enzymatically incorporated Cap 1 for mRNA capping, and a prefusion-stabilized spike configuration. An alternative design, BNT162b1, encodes a soluble, secreted trimerized receptor-binding domain (RBD-foldon) rather than the full-length spike. Advanced stabilization approaches, such as the S6P mutation (incorporating KV986PP plus four additional proline substitutions at F817P, A892P, A899P, and A942P), have been explored in next-generation candidates.

Effects on Antigenicity

Antibody Responses

Tozinameran elicited robust antibody responses across preclinical and clinical studies. In rhesus macaques, prime-boost vaccination produced neutralizing geometric mean titers 10.2 to 18.0 times higher than those in convalescent human serum panels. The vaccine induced dose-dependent increases in pseudovirus neutralization titers in mice, with neutralizing antibodies remaining detectable at 3 months post-vaccination in humans.

Comparative analyses demonstrated superiority over some platforms. BNT162b2-elicited sera showed higher titers and better neutralizing capacity compared to CVnCoV-elicited sera. The vaccine preserved neutralizing antibody activity against the B.1.1.7 variant, though neutralizing capacity was significantly impacted against the B.1.351 variant. Anti-RBD titers from vaccine-elicited sera exceeded those from convalescent sera.

Design elements differentially affected antibody production. The ionizable lipid component influenced neutralizing antibody generation, with SM-102 (used in Moderna’s vaccine) producing higher neutralizing activity at days 14 and 35 post-vaccination compared to ALC-0315. UTR sequences from Pfizer-BioNTech’s 5’ region and Moderna’s 3’ region demonstrated superior performance in supporting mRNA translation and antibody production.

T-Cell Responses

The vaccine generated strong cellular immunity characterized by TH1-type CD4+ and IFNγ+ CD8+ T-cell responses in both mice and rhesus macaques. This TH1-biased response profile is favorable for vaccine safety and efficacy. CD4+ T-cell responses were identified in all COVID-19 patients and correlated with IgG and IgA antibody titers. The vaccine facilitated efficient presentation of peptide fragments to CD8+ T cells through intracellular processing.

The full-length prefusion-stabilized spike design (BNT162b2) provided a broader T-cell epitope range compared to the RBD-only construct (BNT162b1), contributing to the selection of BNT162b2 for clinical development. The balanced immune response included secretion of both TH1 cytokines (IFN-γ, IL-2, TNF-α) and TH2 cytokines (IL-4, IL-5, IL-13) in certain contexts.

Epitope Recognition and Structural Considerations

A critical finding emerged regarding epitope recognition patterns. Peptide array analyses identified 37 linear epitopes across the spike protein, with 26 epitopes almost exclusively recognized by convalescent sera but not vaccine-elicited sera. These 26 epitopes predominantly mapped to regions masked in the prefusion structure but exposed in the post-fusion conformation. Specifically, three epitopes in the conserved central helix were only exposed post-fusion.

The prefusion stabilization achieved through K986P and V987P mutations reduced structural flexibility and conferred resistance to proteolytic processing. While this stabilization enhanced presentation of the ACE2 binding site and other key neutralizing epitopes, it simultaneously masked epitopes accessible during natural infection. Vaccine-elicited sera strongly recognized linear epitopes harboring K417, E484, and N501 residues, which are critical for ACE2 binding.

The structural design resulted in approximately 20% of spike trimers adopting the one-RBD ‘up’ conformation, creating a dynamic equilibrium between RBD positions. This equilibrium allowed exposure of epitopes that would otherwise remain buried, enhancing immune recognition while maintaining the prefusion-stabilized state.

mRNA Stability and Processing

The cellular fate of vaccine mRNA significantly influenced antigenicity. Studies revealed that mRNA-1273 (Moderna) underwent more potent poly(A) tail re-adenylation by TENT5A compared to BNT162b2, correlating with higher membrane association and antigen production. Re-adenylation extended poly(A) tails from approximately 100 to 200 nucleotides, stabilizing mRNA and enhancing translation. TENT5A deficiency reduced specific immunoglobulin production in mice immunized with mRNA vaccines.

The capping strategy influenced re-adenylation efficiency, with enzymatically incorporated Cap 1 producing several-fold more antigen than CleanCap-equipped mRNA. The m1Ψ modification enhanced mRNA stability and translation while reducing innate immune signaling, improving overall antigen presentation. However, varying N1-methylpseudouridine content at wobble positions showed little effect on neutralizing antibody production.

Comparative Design Effects

Direct comparisons between BNT162b1 and BNT162b2 revealed that while both candidates elicited strong immune responses, BNT162b2 provided superior protection of the lower respiratory tract from viral RNA. BNT162b2 was selected for clinical advancement based on greater tolerability and broader T-cell epitope coverage, despite comparable immunogenicity.

Comparison with CVnCoV, an unmodified mRNA vaccine encoding a stabilized spike, highlighted the importance of nucleoside modification. BNT162b2 and Moderna (both using modified nucleosides) achieved over 94% efficacy, while CVnCoV demonstrated 48% efficacy. The modified RNA in BNT162b2 (30 μg dose) showed higher efficacy and immune responses compared to unmodified RNA in CVnCoV (12 μg dose). Reactogenicity of unmodified RNA limited achievable dosing in CVnCoV, potentially impacting antigenicity.

Component-level comparisons demonstrated that UTR selection affected translation efficiency. Pfizer-BioNTech’s 5’ UTR outperformed Moderna’s counterpart, while Moderna’s 3’ UTR exceeded Pfizer-BioNTech’s version. These UTR differences contributed to overall antigen expression levels and subsequent immune responses.

Advanced stabilization strategies, exemplified by the S6P mutation, enhanced immunogenicity beyond the standard P2 design. The S6P mutation (incorporating six proline substitutions) elicited significantly stronger B and T cell responses with more durable neutralizing antibodies compared to S2P-based vaccines. This enhanced stability preserved the prefusion conformation more effectively, leading to improved immune recognition and broader cross-variant neutralization.

Synthesis: Reconciling Epitope Diversity with Neutralizing Potency

The studies revealed an apparent paradox: prefusion-stabilized spike designs like BNT162b2 produce fewer recognized linear epitopes than natural infection yet elicit higher neutralizing antibody titers than convalescent sera. This divergence reflects fundamental differences in antigen presentation rather than a deficiency in either response.

Mechanism of Differential Epitope Exposure The prefusion stabilization through K986P and V987P mutations constrains spike protein flexibility, preventing conformational transitions that would expose post-fusion epitopes. During natural infection, spike proteins undergo fusion-mediated conformational changes, exposing epitopes in the central helix and other regions that become accessible only in post-fusion states. The 26 epitopes preferentially recognized by convalescent sera map predominantly to these conformational-dependent regions. In contrast, the vaccine-stabilized prefusion conformation maintains epitopes critical for ACE2 binding and neutralization in an accessible state, while masking conformational epitopes.

Functional Consequences: Quality Over Quantity The reduced epitope diversity in vaccine-elicited responses does not indicate inferior immunity; rather, it reflects focused recognition of neutralizing determinants. Vaccine-elicited antibodies target the RBD and S1 domain with high affinity, particularly epitopes containing K417, E484, and N501—residues essential for ACE2 binding. This focused response produces neutralizing titers 10-18 times higher than convalescent sera, demonstrating that epitope quality (neutralizing capacity) outweighs quantity (total epitopes recognized).

Natural infection presents both prefusion and post-fusion spike conformations, generating antibodies to a broader epitope repertoire that includes non-neutralizing targets. While this broader response may provide advantages for variant recognition, it dilutes the neutralizing antibody fraction. The vaccine’s prefusion-only presentation concentrates immune responses on functionally critical epitopes.

Design Element Contributions to Antigenicity Multiple design elements synergistically enhance antigenicity through distinct mechanisms:

• The m1Ψ modification operates primarily through enhanced mRNA stability and reduced innate immune interference, increasing antigen expression duration and quantity.
• UTR sequences regulate translation initiation and mRNA stability, with optimal combinations (Pfizer’s 5’ UTR and Moderna’s 3’ UTR) providing superior translation efficiency.
• The poly(A) tail undergoes enzymatic extension by TENT5A in macrophages, extending from 100 to 200 nucleotides and stabilizing membrane-associated mRNA to prolong antigen production.
• The prefusion stabilization itself provides structural advantages beyond epitope presentation.

Implications for Variant Protection The prefusion-focused epitope recognition has mixed implications for variant responses. While preserved neutralization against B.1.1.7 demonstrates some cross-variant protection, significantly reduced neutralization of B.1.351 reveals limitations. Variants with mutations in conserved prefusion epitopes (particularly K417, E484, N501) can escape vaccine-elicited immunity more readily than they escape convalescent immunity, which targets additional epitopes in the central helix and other regions.

However, advanced designs incorporating broader stabilization (S6P) or self-amplifying platforms (ARCT-154) demonstrate enhanced cross-variant neutralization. The sustained antigen production from self-amplifying mRNA moves immune profiles toward activating phenotypes with broad antigenic coverage, suggesting that prolonged antigen exposure may partially compensate for reduced epitope diversity by allowing affinity maturation against variant epitopes.

Trade-offs in Design Optimization Design choices involve inherent trade-offs between different immune response characteristics. Maximum neutralizing potency (achieved through strict prefusion stabilization) comes at the cost of epitope breadth. Higher mRNA doses and enhanced stability (through modifications, optimal UTRs, and re-adenylation) increase antigen expression but may alter the balance between humoral and cellular responses.

The selection of BNT162b2 over BNT162b1 illustrates these trade-offs: the full-length spike provides broader T-cell epitope coverage and better respiratory tract protection, while the RBD-only construct offers high-avidity ACE2 binding through flexible tethering.

Conclusion Tozinameran’s mRNA design achieves high antigenicity through prefusion stabilization that optimally presents neutralizing epitopes, nucleoside modifications that enhance expression, and structural elements that support mRNA stability and translation. The reduced linear epitope recognition compared to natural infection represents a feature rather than limitation—focusing immune responses on functionally critical neutralizing determinants while sacrificing recognition of conformational epitopes with limited protective value. This design philosophy prioritizes neutralizing antibody quality and T-cell breadth over total antibody diversity, an approach validated by clinical efficacy exceeding 95% despite narrower epitope targeting than natural infection.